EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Apellis Announces Craig Wheeler to Join the Board of Directors
Apellis Pharmaceuticals, Inc. (APLS) has announced the immediate appointment of Craig Wheeler to its Board of Directors. Wheeler, the founder and CEO of Headwaters Biotech
Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company
Highlights LONDON, UK and Boston, MA, 7 April 2025 – Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted
Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline
Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as Chair Cambridge, UK,
Apellis Present Pivotal VALIANT Results at Kidney Week Highlighting Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
WALTHAM, Mass. October 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT
Dr. Falk Pharma acquires spinout Kynos Therapeutics to develop its novel KMO inhibitors for acute pancreatitis
29 October 2024, Dr. Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the
Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease
Hamburg, Germany, October 15th, 2024 – Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with
Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001
Brighton, UK, 26 September 2024: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceuticalcompany dedicated to the discovery and development of novel therapies to improve the lives of